

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/735EED26B28EN.html>

Date: January 2018

Pages: 37

Price: US\$ 3,500.00 (Single User License)

ID: 735EED26B28EN

Abstracts

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H1 2018

SUMMARY

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

The latest report 78 kda Glucose Regulated Protein - Pipeline Review, H1 2018, outlays comprehensive information on the 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Binding immunoglobulin protein (BiP) or 78 kDa glucose-regulated

protein (GRP-78) is a protein encoded by HSPA5 gene. It plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. It is involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology and Immunology which include indications Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Glioma, Melanoma, Pancreatic Ductal Adenocarcinoma, Rheumatoid Arthritis and Solid Tumor.

Furthermore, this report also reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)

The report reviews 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics and enlists all their major and minor projects

The report assesses 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Luminal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - OVERVIEW

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - THERAPEUTICS DEVELOPMENT

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - THERAPEUTICS ASSESSMENT

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - COMPANIES INVOLVED IN THERAPEUTICS DEVELOPMENT

Intezyne Technologies Inc

Nuevolution AB

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - DRUG PROFILES

HA-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IT-139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rasolvir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GRP78 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - DORMANT PRODUCTS

78 KDA GLUCOSE REGULATED PROTEIN (ENDOPLASMIC RETICULUM LUMENAL CA(2+) BINDING PROTEIN GRP78 OR HEAT SHOCK 70 KDA PROTEIN 5 OR IMMUNOGLOBULIN HEAVY CHAIN BINDING PROTEIN OR HSPA5) - PRODUCT DEVELOPMENT MILESTONES

Featured News & Press Releases

Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70...

Pancreatic Cancer

Mar 31, 2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium

May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012

Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer

Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339

Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339

Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents

Sep 20, 2011: Niiki Pharma Announces Positive Interim Data From Ongoing Clinical Trial Of Anti-Cancer Agent NKP-1339

Jun 01, 2011: Niiki Pharma To Present Interim Data From Phase I Study Of NKP-1339 At ASCO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Intezyne Technologies Inc, H1 2018
Pipeline by Nuevolution AB, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Intezyne Technologies Inc

Nuevolution AB

I would like to order

Product name: 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/735EED26B28EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/735EED26B28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970